Hemostasis Diagnostic Devices and Equipment Market Report 2026

The hemostasis diagnostic devices and equipment market size has grown rapidly in recent years. It will grow from $5.66 billion in 2025 to $6.42 billion in 2026 at a compound annual growth rate (CAGR) of 13.4%. The growth in the historic period can be attributed to increasing incidence of bleeding disorders, expansion of surgical procedures requiring coagulation monitoring, growth of hospital laboratory services, adoption of standardized clotting tests, availability of advanced coagulation reagents.

The hemostasis diagnostic devices and equipment market size is expected to see rapid growth in the next few years. It will grow to $10.12 billion in 2030 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing demand for rapid bedside diagnostics, rising adoption of AI-assisted coagulation analysis, expansion of personalized anticoagulant therapy, growing investments in advanced laboratory infrastructure, increasing focus on preventive diagnostics. Major trends in the forecast period include increasing deployment of automated coagulation analyzers, rising demand for point-of-care hemostasis testing, growing integration of digital result interpretation tools, expansion of comprehensive clotting analysis systems, enhanced focus on rapid diagnostic turnaround.

The increasing number of surgical procedures is expected to drive the growth of the hemostasis diagnostic devices and equipment market in the future. Surgical procedures involve medical interventions that require making incisions or using invasive techniques to access and treat internal or external areas of the body. The rise in surgical procedures is largely due to the aging population, which leads to a higher prevalence of chronic and complex medical conditions that require surgical intervention. Hemostasis diagnostic devices play a critical role in these procedures by improving the management of blood clotting, reducing risks, and enhancing overall surgical efficiency, which ultimately results in better patient outcomes. For example, in April 2025, the British Broadcasting Corporation, a UK-based public service broadcaster, reported that approximately 27,462 cosmetic surgical procedures were carried out in 2024, marking a 5% increase from 2023, with more than 90% of the procedures performed on women. As such, the rising number of surgical procedures is fueling the growth of the hemostasis diagnostic devices and equipment market.

Major companies in the hemostasis diagnostic devices and equipment market are increasingly focusing on technological innovations, such as inhibitor-specific coagulation testing, to enhance patient safety, optimize anticoagulation therapy, and reduce the risk of bleeding or thrombotic events in individuals taking direct oral anticoagulants (DOACs). These tests allow laboratories and clinicians to accurately assess anticoagulant activity, adjust dosages as needed, and provide personalized therapy management. For example, in February 2024, Roche Diagnostics, a Switzerland-based manufacturer of diagnostic equipment and reagents for research and medical diagnostic applications, introduced three new Factor Xa inhibitor coagulation tests for its cobas platforms. These tests are designed to measure the activity of apixaban, rivaroxaban, and edoxaban in patient plasma samples. The tests aim to provide rapid, accurate, and reliable results to guide clinical decisions in scenarios like surgery, emergency care, or suspected bleeding complications. This launch aligns with the growing trend toward personalized anticoagulation management, improving safety and efficacy for patients on direct Factor Xa inhibitor therapy, while also offering laboratories standardized and automated assay solutions.

In March 2023, Werfen, S.A., a Europe-based company specializing in diagnostic instruments and reagents for hospitals and laboratories, acquired Immucor, Inc. for an undisclosed amount. This acquisition allows Werfen, S.A. to enhance its diagnostic solutions and improve patient care. Immucor, Inc., a US-based company, is known for manufacturing diagnostic products and systems primarily for blood transfusion and immunohematology.

Major companies operating in the hemostasis diagnostic devices and equipment market are Baxter International Inc., Johnson & Johnson, Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Company, Chrono-Log Corporation, F. Hoffmann-La Roche Ltd., Grifols S.A., Siemens AG, Thermo Fisher Scientific Inc., Trinity Biotech plc., Ethicon Inc., B. Braun Interventional Systems Inc., Bio-Rad Laboratories Inc., CareFusion Corporation, Danaher Corporation, Diagnostica Stago SAS, Haemonetics Corporation, QuidelOrtho Corp, STAGO.

North America was the largest region in the global hemostasis diagnostic devices and equipment market in 2025. Asia-Pacific was the second-largest region in the hemostasis diagnostic devices and equipment market. The regions covered in the hemostasis diagnostic devices and equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemostasis diagnostic devices and equipment market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.

Tariffs are influencing the hemostasis diagnostic devices and equipment market by increasing costs of imported analyzers, reagents, testing kits, electronic components, and precision measurement systems. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported diagnostic instruments, while Asia-Pacific faces increased export-related cost pressures. These tariffs are raising test costs and influencing procurement strategies. However, they are also encouraging local reagent manufacturing, domestic analyzer assembly, and innovation in cost-efficient diagnostic solutions.

The hemostasis diagnostic devices and equipment market research report is one of a series of new reports that provides hemostasis diagnostic devices and equipment market statistics, including hemostasis diagnostic devices and equipment industry global market size, regional shares, competitors with a hemostasis diagnostic devices and equipment market share, detailed hemostasis diagnostic devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the hemostasis diagnostic devices and equipment industry. This hemostasis diagnostic devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemostasis diagnostic devices and equipment are specialized tools used to assess the blood clotting process and diagnose bleeding disorders. These devices enable healthcare professionals to monitor and evaluate different stages of hemostasis, including clot formation, stabilization, and dissolution. They play a crucial role in diagnosing conditions such as hemophilia, vitamin K deficiencies, and other clotting disorders, ensuring effective treatment and management.

The primary product categories within hemostasis diagnostic devices and equipment consist of analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits. Hemostasis diagnostic analyzers are specifically designed tools used to forecast the causes of bleeding during surgery by detecting any underlying hemostatic abnormalities. These diagnostic devices and equipment come in various formats, including automated, semi-automated, and manual options, and they are commonly employed in hospitals, clinics, independent diagnostic laboratories, and other medical settings.

Hemostasis diagnostic devices and equipment consist of sales of instruments such as analyzers, coagulation instruments, other hemostasis instruments, and reagents and kits that are used in hemostasis diagnostics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.